12+
Years In Biotech & Capital Markets
1
Startups Initiated
2,576
LinkedIn Followers
Shankar’s Journey
Joined Roivant Sciences as an Analyst.
2014
Became Vice President of Global Medical Affairs at Axovant.
2017
Named Chief Business Officer of Axovant Sciences.
2019
2016
Promoted to Vice President of Medical and Scientific Communications at Axovant.
2018
Promoted to Senior Vice President of Business Development and Operations at Axovant.
2019
Co-founded Kriya Therapeutics as Chairman and CEO to build a fully integrated gene therapy engine controlling discovery, development, manufacturing, and computational biology under one roof.
About Kriya Therapeutics
Founded - 2019 | Morrisville / Research Triangle Park, NC | Stage -Late-stage private biotech
Highlight
Kriya Therapeutics develops gene therapies through an integrated discovery, development, manufacturing, and computational platform.
Problem
Gene therapy has enormous potential, but development remains capital-intensive, technically complex, and hard to scale. Many companies depend on fragmented manufacturing and platform partners, which can slow execution.
USP
Kriya is building a fully integrated gene therapy engine rather than a single-asset biotech. The company has raised hundreds of millions of dollars and has been valued in the billion-dollar range by some public startup data sources.
Key Milestones
2019
Founded to build an integrated gene therapy company.
2021
Expanded operations and platform development across gene therapy programs.
2023
Raised a $270 million Series C led by Patient Square Capital.
2023-24
Continued scaling engineering, manufacturing, and computational platforms.
2025
Public startup data and press reports placed Kriya among the most heavily funded NC biotech companies.
In Their Own Words:
"Unlocking the full potential of gene therapy as a modality."
Connect: